Skip to main content

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Francina Munell Casadesus

Institutions of which they are part

Main researcher
Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Acciones de los receptores de andrógenos y estrógenos en la diferenciación miogénica y su modulación como estrategia terapéutica para revertir la diferenciación anómala del músculo deficiente en distrofina

IP: Francina Munell Casadesus
Collaborators: Mireia Del Toro Riera, Mario Marotta Baleriola
Funding agency: Instituto de Salud Carlos III
Funding: 154275
Reference: PI09/00097
Duration: 01/01/2010 - 31/10/2013

Estudio del metabolismo de la glucosa y el glucógeno en células musculares en cultivo y fibroblastos de paciente afecto de la forma infantil de la enfermedad de Pome y controles sanos

IP: Mireia Del Toro Riera
Collaborators: Francina Munell Casadesus
Funding agency: Fundación Genzyme
Funding: 10000
Reference: FEEL2008/01
Duration: 03/04/2009 - 02/04/2011

Grup de Recerca en Neurologia Infantil HUVH

IP: Alfons Macaya Ruíz
Collaborators: Susana Boronat Guerero, Francina Munell Casadesus, Miquel Raspall Chaure, Mireia Del Toro Riera, Marta Rebull Santamaria, Mario Marotta Baleriola, Grup de Recerca en Neurologia Infantil HUVH
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 41600
Reference: 2009 SGR 78
Duration: 01/01/2010 - 30/04/2014

Acciones de la SHBG y de los receptores de estrógenos en el desarrollo y la progresión a la hormono-resistencia del cáncer de próstata.

IP: Francina Munell Casadesus
Collaborators: Joan Morote Robles
Funding agency: Instituto de Salud Carlos III
Funding: 108215
Reference: PI020772
Duration: 06/11/2002 - 06/11/2005

Related news

The donation will enable further characterisation of patients with this rare disease, the identification of new biomarkers and the exploration of innovative therapies.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Related professionals

Miguel Del Campo Casanelles

Miguel Del Campo Casanelles

Head of group
Genetics Medicine
Read more
Alba García Moral

Alba García Moral

Predoctoral researcher
Growth and Development
Read more
Gala Granero LLoria

Gala Granero LLoria

Predoctoral researcher
Pharmacokinetic Nanoparticles
Read more
Ignacio Vaz-Romero Trueba

Ignacio Vaz-Romero Trueba

Predoctoral researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.